Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3–5: is it significant?

Prabhu, Ravindra Attur and Mareddy, Aswani Srinivas and Nagaraju, Shankar Prasad and Rangaswamy, Dharshan and Guddattu, Vasudeva (2019) Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3–5: is it significant? International Urology and Nephrology, 51. pp. 1229-1230. ISSN 0301-1623

[img] PDF
6914 DisplayPdf.pdf - Published Version
Restricted to Registered users only

Download (421kB) | Request a copy

Abstract

Purpose To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3–5.Methods We estimated plasma lactate in patients of CKD stage 3 and worse who were continuing metformin on their own prior to stopping the drug.Result Of 40 patients included, median duration of T2DM was 60 months (interquartile range IQR 24–120). The mean serum creatinine was 309.4 ± 159.1 μmol/L and mean eGFR was 27.82 ± 12.93 mL/min/1.73 m2 with 3 (7.5%), 16 (40%), 11 (27.5%) and 10 (25%) in CKD stages 3a, 3b, 4 and 5, respectively. They were receiving metformin for a median duration of 24 months (IQR 12.5–60), an average dose of 896 ± 350 mg per day. The median of plasma lactate was 1.36 mmol/L (IQR 1.11–1.75 mmol/L) with three (7.5%) having levels above normal, two (20%) in CKD stage 5 and one (9.1%) in stage 4.Conclusion Metformin can be safely used in CKD stage 3 and with regular measurement of plasma lactate in later stages

Item Type: Article
Uncontrolled Keywords: Chronic kidney disease; Lactic acidosis; Metformin; Type 2 diabetes mellitus
Subjects: Departments at MU > Statistics
Medicine > KMC Manipal > Nephrology
Depositing User: KMC Library
Date Deposited: 06 Aug 2019 08:49
Last Modified: 06 Aug 2019 08:49
URI: http://eprints.manipal.edu/id/eprint/154272

Actions (login required)

View Item View Item